Key facts
- Endolumik’s last known valuation is $20.0M (Jun 2025).
- It has raised $3.8M across 2 recorded rounds; the latest was Seed Round ($1.0M) in Jun 2024.
- Notable investors include Texas Medical Center, Innovation Works, Calypso Holdings & Investments, Country Roads Angel Network, Cutwater Capital — 10 tracked in total.
- Endolumik has filed 2 Form Ds with the SEC since 2023, most recently Jun 2025 ($1.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Endolumik
Funding rounds
2 roundsAbout Endolumik
Developer of surgical devices designed to improve safety and precision in minimally invasive procedures through fluorescence-guided visualization. The company offers a near-infrared gastric calibration tube and a growing portfolio of illumination technologies supported by proprietary IP, enabling bariatric, general, and colorectal surgeons to enhance intraoperative visibility and improve surgical outcomes.
- Sector
- Healthcare
- HQ
- Morgantown, WV, United States
- Founded
- 2020
- Employees
- 6
- Website
- endolumik.com/
- Ownership
- Privately Held (backing)
Endolumik doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Endolumik shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Endolumik in its N-PORT filings yet. We sweep new filings monthly.